Literature DB >> 20153253

The immunobiology of aluminium adjuvants: how do they really work?

Christopher Exley1, Peter Siesjö, Håkan Eriksson.   

Abstract

Aluminium adjuvants potentiate the immune response, thereby ensuring the potency and efficacy of typically sparingly available antigen. Their concomitant critical importance in mass vaccination programmes may have prompted recent intense interest in understanding how they work and their safety. Progress in these areas is stymied, however, by a lack of accessible knowledge pertaining to the bioinorganic chemistry of aluminium adjuvants, and, consequently, the inappropriate application and interpretation of experimental models of their mode of action. The objective herein is, therefore, to identify the many ways that aluminium chemistry contributes to the wide and versatile armoury of its adjuvants, such that future research might be guided towards a fuller understanding of their role in human vaccinations. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20153253     DOI: 10.1016/j.it.2009.12.009

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  49 in total

1.  Comparison of PLA microparticles and alum as adjuvants for H5N1 influenza split vaccine: adjuvanticity evaluation and preliminary action mode analysis.

Authors:  Weifeng Zhang; Lianyan Wang; Yuan Liu; Xiaoming Chen; Jiahui Li; Tingyuan Yang; Wenqi An; Xiaowei Ma; Ruowen Pan; Guanghui Ma
Journal:  Pharm Res       Date:  2013-10-30       Impact factor: 4.200

2.  Unethical approach.

Authors:  Jürgen Fridrich
Journal:  Dtsch Arztebl Int       Date:  2015-03-20       Impact factor: 5.594

Review 3.  Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.

Authors:  Calvin C Willhite; Nataliya A Karyakina; Robert A Yokel; Nagarajkumar Yenugadhati; Thomas M Wisniewski; Ian M F Arnold; Franco Momoli; Daniel Krewski
Journal:  Crit Rev Toxicol       Date:  2014-10       Impact factor: 5.635

4.  Aluminum (Oxy)Hydroxide Nanosticks Synthesized in Bicontinuous Reverse Microemulsion Have Potent Vaccine Adjuvant Activity.

Authors:  Xu Li; Stephanie Hufnagel; Haiyue Xu; Solange A Valdes; Sachin G Thakkar; Zhengrong Cui; Hugo Celio
Journal:  ACS Appl Mater Interfaces       Date:  2017-06-29       Impact factor: 9.229

5.  Comment on: "Safety of Human Papillomavirus Vaccines: An Updated Review".

Authors:  Manuel Martínez-Lavín
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

6.  Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex.

Authors:  Zoltan Beck; Oscar B Torres; Gary R Matyas; David E Lanar; Carl R Alving
Journal:  J Control Release       Date:  2018-02-09       Impact factor: 9.776

Review 7.  ASIA syndrome, calcinosis cutis and chronic kidney disease following silicone injections. A case-based review.

Authors:  Giuseppe Barilaro; Claudia Spaziani Testa; Antonella Cacciani; Giuseppe Donato; Mira Dimko; Amalia Mariotti
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

8.  Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer.

Authors:  Joseph P Nkolola; Ann Cheung; James R Perry; Darrick Carter; Steve Reed; Hanneke Schuitemaker; Maria Grazia Pau; Michael S Seaman; Bing Chen; Dan H Barouch
Journal:  Vaccine       Date:  2014-02-18       Impact factor: 3.641

9.  Efficient antigen cross-presentation through coating conventional aluminum adjuvant particles with PEI.

Authors:  Hongyan Ren; Yongbin Mou; Lin Lin; Lixin Wang; Hongming Hu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

10.  Disparate adjuvant properties among three formulations of "alum".

Authors:  Derek W Cain; Sergio E Sanders; Michael M Cunningham; Garnett Kelsoe
Journal:  Vaccine       Date:  2012-11-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.